Product Name: ROR2 (642-649) pY645+pY646
Product Number: PE-04APM99
Size: 200 µg      Price:74.00
1 mg      $US148.00
5 mg      325.00
Peptide Name: ROR2 (642-649) pY645+pY646

Product Use: Services as a blocking peptide for use with the ROR2-pY645+pY646 rabbit polyclonal antibody (Cat. No.: AB-PK802) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T-loop between subdomains VII and VIII. Y645 and Y646 phosphorylation stimulate phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: AAD-pY-pY-KLL

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys
Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 1289.3 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: ROR2 - pY645+pY646 phosphosite-specific antibody (Cat. No.: AB-PK802)

Scientific Background: ROR2 (NTRKR2) is a protein-tyrosine kinase of the TK group and Ror family. It is an orphan receptor kinase that is hypothesized to function in the early formation of chrondrocytes (cartilage cells) and growth plate development. ROR2 expression is generally highest during embryonic development and will gradually decrease as cells terminally differentiate. The ROR2 protein is a transmembrane protein that contains a highly conserved region of 10 cysteine residues, predicted through homology to be a binding domain for wnt ligands. Wnt5a has been identified to utilize ROR2 as a co-receptor for non-canonical Wnt signalling. ROR2 is known to phosphorylate YWHAB, which induces osteogenesis and bone formation. Therefore, the ROR2 protein is implicated in the regulation of skeletal development. Furthermore, ROR2 is also required for the migration of cells to form the mammalian palate and for the formation of filopodia in mouse embryonic fibroblasts, a requirement for cell migration. ROR2 appears to be an oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Gain-of-function mutations in the ROR2 protein are associated specifically in the promotion of the epithelial to mesenchymal transition (EMT), which is a key step during the metastasis of cancer cells. In animal studies, the injection of ROR2 deficient human melanoma cells into a mouse models results in significantly decreased cell motility and spreading as compared to cells that express ROR2, further indicating a role for ROR2 in cancer metastasis. Consequently, ROR2 is suggested to play a role in the promotion of metastasis, specifically in melanoma cells, and contributing to the progression of cancer and acting as an oncoprotein. Aberrant expression of ROR2 has been implicated in gastric, osteosarcoma, mestatic melanoma, prostate, renal cell and squamous cell carcinomas. In prostate, osteosarcomas and metastatic melanomas, Wnt5a/ROR2 receptor complex formation was implicated as the mechanism for cancer progression.